High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance.
Childhood cancer survivors often experience complications related to cancer and its treatment that may adversely affect quality of life and increase the risk of premature death. The purpose of this manuscript is to review how data derived from Childhood Cancer Survivor Study (CCSS) investigations have facilitated identification of childhood cancer survivor populations at high risk for specific organ toxicity and secondary carcinogenesis and how this has informed clinical screening practices. Articles previously published that used the resource of the CCSS to identify risk factors for specific organ toxicity and subsequent cancers were reviewed and results summarized. CCSS investigations have characterized specific groups to be at highest risk of morbidity related to endocrine and reproductive dysfunction, pulmonary toxicity, cerebrovascular injury, neurologic and neurosensory sequelae, and subsequent neoplasms. Factors influencing risk for specific outcomes related to the individual survivor (eg, sex, race/ethnicity, age at diagnosis, attained age), sociodemographic status (eg, education, household income, health insurance) and cancer history (eg, diagnosis, treatment, time from diagnosis) have been consistently identified. These CCSS investigations that clarify risk for treatment complications related to specific treatment modalities, cumulative dose exposures, and sociodemographic factors identify profiles of survivors at high risk for cancer-related morbidity who deserve heightened surveillance to optimize outcomes after treatment for childhood cancer.
Hudson
Melissa M
MM
St Jude Children's Research Hospital, Memphis, TN 38105, USA. Melissa.hudson@stjude.org
Mulrooney
Daniel A
DA
Bowers
Daniel C
DC
Sklar
Charles A
CA
Green
Daniel M
DM
Donaldson
Sarah S
SS
Oeffinger
Kevin C
KC
Neglia
Joseph P
JP
Meadows
Anna T
AT
Robison
Leslie L
LL
D000293:Adolescent; D000328:Adult; D002561:Cerebrovascular Disorders / Q000453:epidemiology; D002648:Child; D015897:Comorbidity; D004700:Endocrine System Diseases / Q000453:epidemiology; D005260:Female; D006130:Growth Disorders / Q000453:epidemiology; D006801:Humans; D008171:Lung Diseases / Q000453:epidemiology; D008297:Male; D008403:Mass Screening / Q000706:statistics & numerical data; D009369:Neoplasms / Q000401:mortality*; D016609:Neoplasms, Second Primary / Q000453:epidemiology* / Q000517:prevention & control*; D009422:Nervous System Diseases / Q000453:epidemiology; D018570:Risk Assessment; D017741:Survivors / Q000706:statistics & numerical data*; D014481:United States / Q000453:epidemiology; D055815:Young Adult